Whalesbook
Toh bhaiyo aur behno, Glenmark Pharmaceuticals ne finally US mein apna Vancomycin hydrochloride injection launch kar diya hai. Ye company ke liye injectable drugs market mein ek bada move hai, jiska size potential $37.9 million per year tak ho sakta hai.
Ab ye market chhota nahi hai, bhai. Generic injectable drugs ka US market toh $17.91 billion se badh kar $39.10 billion tak jaane wala hai 2034 tak, matlab saal ka 9.15% growth! Glenmark ka current market cap lagbhag ₹65,637 Crore (ya $7.87 billion USD) hai aur P/E ratio 53.92 hai, jo sector average 24.31 se kaafi upar hai.
Competition bhi tight hai. Fresenius SE & Co. KGaA jaisi badi companies bhi hain, jinka valuation $115.35 billion hai. Glenmark ka focus specific $37.9 million wale segment par hai, jisko 2024 mein $108.1 million ka estimate kiya gaya tha.
Par yahan aata hai asli twist! Glenmark ki manufacturing practices ko lekar FDA ke purane warnings hain. Company ko pehle bhi FDA se warning letters mili hain aur kuch products recall bhi hue hain. Indian plants mein quality control aur manufacturing problems ko theek se investigate na karne ke liye late 2022 aur mid-2025 mein warnings mili thi. Isse unki quality par sawaal uthta hai aur new products ke launch par asar pad sakta hai. FDA ke strict rules follow karna injectable market mein bahut important hai, aur Glenmark ke liye ye ek bada challenge hai.
Bhale hi ye issues hain, par analysts abhi bhi positive hain. Kaafi log 'Buy' ya 'Strong Buy' recommend kar rahe hain, haan kuch log valuation ko dekh kar thoda cautious hain. Glenmark Pharma ka Net Sales aur Profit after Tax recent mein achha grow hua hai. Analysts ne target price around 2,300.10 INR set kiya hai. Dekhna hoga ki Glenmark ye naya launch apne injectable portfolio mein kaise fit karta hai market competition aur strict regulations ke beech.